Breaking News, Collaborations & Alliances

Biogen, ViGeneron Enter Gene Therapy Collaboration

Will develop and commercialize gene therapy products based on adeno-associated virus vectors to treat inherited eye diseases.

By: Contract Pharma

Contract Pharma Staff

ViGeneron GmbH, a gene therapy company, has announced a global collaboration and licensing agreement with Biogen Inc. to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases.   The companies will use ViGeneron’s proprietary vgAAV, novel engineered AAV capsids, to efficiently transduce retinal cells via intravitreal injections.   “Gene therapy has become a clinical reality. At ViGeneron, we are dedicated to developing in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters